Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “MRD”

370 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 370 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06570915
What this trial is testing

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

Who this might be right for
ALL, Adult
Institute of Hematology & Blood Diseases Hospital, China 20
Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Very early researchNot Yet RecruitingNCT06434376
What this trial is testing

MRD-positive Colorectal Cancer Patients Combined With Personalized Immune Regulation Diagnosis

Who this might be right for
Colorectal Cancer
Second Affiliated Hospital of Wenzhou Medical University 10
Not applicableUnknownNCT02872662
What this trial is testing

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Who this might be right for
MDSSCTMRD
Nordic MDS Group 200
Not applicableStudy completedNCT02716103
What this trial is testing

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 45
Not applicableStudy completedNCT06000306
What this trial is testing

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Who this might be right for
Measurable Residual Disease
Zhejiang University 192
Not applicableLooking for participantsNCT06941389
What this trial is testing

Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease

Who this might be right for
Sickle Cell Disease (SCD)
University of Rochester 480
Testing effectiveness (Phase 2)Looking for participantsNCT05872724
What this trial is testing

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

Who this might be right for
Cervical Cancer
Suzhou Municipal Hospital 32
Not applicableLooking for participantsNCT06198868
What this trial is testing

MRD-guided Prognosis Prediction and Adjuvant Treatment Based on CTC and ctDNA in NSCLC

Who this might be right for
Non-small Cell Lung Cancer
Jiangsu Cancer Institute & Hospital 60
Not applicableNot Yet RecruitingNCT06856798
What this trial is testing

Construction of a Prognostic and Prediction Model for Perioperative Immunotherapy in NSCLC: a Multi - Omics Perspective

Who this might be right for
NSCLC Stage IIIA/BNSCLC Stage II
Ziming Li 120
Testing effectiveness (Phase 2)Ended earlyNCT05317936
What this trial is testing

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Looking for participantsNCT05289687
What this trial is testing

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Who this might be right for
T-cell Acute Lymphoblastic Leukemia
Eastern Cooperative Oncology Group 20
Not applicableUnknownNCT03702088
What this trial is testing

Place of the Hevylite Test in the Evaluation of MRD in Myeloma

Who this might be right for
Myeloma
University Hospital, Montpellier 124
Not applicableLooking for participantsNCT05203003
What this trial is testing

Prospective Evaluation of the Prognostic Impact of Measurable Residual Disease (MRD) Within a Phase III Study Comparing a Fixed Duration Therapy Versus Continuous Therapy With Daratumumab, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma Requiring a First Salvage Treatment.

Who this might be right for
Multiple Myeloma
Assistance Publique - Hôpitaux de Paris 260
Testing effectiveness (Phase 2)UnknownNCT03992170
What this trial is testing

Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive

Who this might be right for
Myeloma Multiple
Azienda Ospedaliera Universitaria Senese 50
Testing effectiveness (Phase 2)Temporarily pausedNCT05642195
What this trial is testing

Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung CancerNon-Small Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung+1 more
National Cancer Institute (NCI) 30
Early research (Phase 1)Study completedNCT02185781
What this trial is testing

Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL)

Who this might be right for
Acute Lymphoblastic LeukemiaComplete Hematologic Remission (CHR)Persistent/Recurrent Minimal Residual Disease (MRD)
Gruppo Italiano Malattie EMatologiche dell'Adulto 6
Testing effectiveness (Phase 2)Looking for participantsNCT06099366
What this trial is testing

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

Who this might be right for
Lymphoblastic Leukemia in Children
Hee Young Ju 116
Not applicableLooking for participantsNCT05255354
What this trial is testing

Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy

Who this might be right for
Follicular LymphomaDiffuse Large B Cell LymphomaMantle Cell Lymphoma
Adaptive Biotechnologies 300
Not applicableLooking for participantsNCT06302699
What this trial is testing

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 80
Load More Results